Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.86 USD | 0.00% |
|
+1.42% | -50.69% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- Low profitability weakens the company.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-50.69% | 19.06M | B- | ||
+23.13% | 46.93B | B- | ||
+37.49% | 39.08B | A | ||
-8.73% | 38.48B | B | ||
+28.09% | 31.01B | B | ||
-12.26% | 26.14B | C | ||
+10.57% | 25.88B | B- | ||
+45.05% | 14.15B | B+ | ||
+32.23% | 12.53B | C+ | ||
-6.56% | 11.36B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MEIP Stock
- Ratings MEI Pharma, Inc.